Table 5.
Impact of TNF-α −1031T/C gene polymorphism on the nutritional status of studied patients
| Factor | CC | CT or TT | p, OR [95% CI] | TT | CT or CC | p, OR [95%CI] | CT | CC or TT | p, OR [95% CI] |
|---|---|---|---|---|---|---|---|---|---|
|
SGA All patients |
|||||||||
| A | 0 | 9 |
0.527 0.385 [0.020–7.420] |
9 | 0 |
0.055 17.0 [0.941–306.99] |
0 | 9 |
0.108 0.093 [0.005–1.688] |
| B and C | 6 (11.3%) | 47 (88.7%) | 28 (52.8%) | 25 (47.2%) | 19 (35.8%) | 34 (64.2%) | |||
| A and B | 1 (2.6%) | 37 (97.4%) |
0.044 9.737 [1.061–89.40] |
31 (81.6%) | 7 (18.4%) |
0.0001 13.29 [3.862–45.70] |
6 (15.8%) | 32 (84.2%) |
0.0023 0.159 [0.048–0.519] |
| C | 5 (20.8%) | 19 (79.2%) | 6 (25%) | 18 (75%) | 13 (54.2%) | 11 (45.8%) | |||
|
SGA Without parenteral nutrition |
|||||||||
| A | 0 | 8 |
0.963 0.929 [0.041–21.16] |
8 | 0 |
0.094 12.14 [0.657–224.57] |
0 | 8 |
0.123 0.101 [0.005–1.865] |
| B and C | 2 (4.9%) | 39 (95.1%) | 24 (58.5%) | 17 (41.5%) | 15 (36.6%) | 26 (63.4%) | |||
| A and B | 1 (2.9%) | 33 (97.1%) |
0.554 0.424 [0.025–7.272] |
27 (79.4%) | 7 (20.6%) |
0.003 7.714 [1.984–29.99] |
6 (17.6%) | 28 (82.4%) |
0.005 0.143 [0.037–0.556] |
| C | 1 (6.7%) | 14 (93.3%) | 5 (33.3%) | 10 (66.7%) | 9 (60%) | 6 (40%) | |||
|
SGA Parenterally nourished |
|||||||||
| A | 0 | 1 |
0.790 0.630 [0.021–18.84] |
1 | 0 |
0.317 5.667 [0.189–169.54] |
0 | 1 |
0.790 0.630 [0.021–18.84] |
| B and C | 4 (33.3%) | 8 (66.7%) | 4 (33.3%) | 8 (66.7%) | 4 (33.3%) | 8 (66.7%) | |||
| A and B | 0 | 4 |
0.218 0.136 [0.006–3.254] |
4 | 0 |
0.023 51.0 [1.705–1525.9] |
0 | 4 |
0.218 0.136 [0.006–3.254] |
| C | 4 (44.4%) | 5 (55.6%) | 1 (11.1%) | 8 (88.9%) | 4 (44.4%) | 5 (55.6%) | |||
|
NRS All patients |
|||||||||
| 2 and 3 | 6 (10%) | 54 (90%) |
0.747 0.596 [0.026–13.83] |
37 (61.7%) | 23 (38.3%) |
0.186 7.979 [0.367–173.59] |
17 (28.3%) | 43 (71.7%) |
0.110 0.080 [0.04–1.762] |
| 4 | 0 | 2 | 0 | 2 | 2 | 0 | |||
| 2 | 0 | 42 |
0.015 38.10 [2.019–719.04] |
31 (73.8%) | 11 (26.2%) |
0.002 6.576 [2.025–21.36] |
11 (26.2%) | 31 (73.8%) |
0.273 0.532 [0.172–1.645] |
| 3 and 4 | 6 (30%) | 14 (70%) | 6 (30%) | 14 (70%) | 8 (40%) | 12 (60%) | |||
|
NRS Without parenteral nutrition |
|||||||||
| 2 and 3 | 2 (4.2%) | 46 (95.8%) |
0.299 0.161 [0.005–5.052] |
32 (66.7%) | 16 (33.3%) |
0.285 5.909 [0.228–153.17] |
14 (29.2%) | 34 (70.8%) |
0.237 0.140 [0.005–3.646] |
| 4 | 0 | 1 | 0 | 1 | 1 | 0 | |||
| 2 | 0 | 34 |
0.107 0.078 [0.004–1.739] |
26 (76.5%) | 8 (23.5%) |
0.017 4.875 [1.326–17.92] |
8 (23.5%) | 26 (76.5%) |
0.112 0.352 [0.097–1.274] |
| 3 and 4 | 2 (13.3%) | 13 (86.7%) | 6 (40%) | 9 (60%) | 7 (46.7%) | 8 (53.3%) | |||
|
NRS Parenterally nourished |
|||||||||
| 2 and 3 | 4 (33.3%) | 8 (66.7%) |
0.790 1.588 [0.053–47.52] |
5 (41.7%) | 7 (58.3%) |
0.648 2.200 [0.075–64.91] |
3 (25%) | 9 (75%) |
0.230 0.123 [0.004–3.782] |
| 4 | 0 | 1 | 0 | 1 | 1 | 0 | |||
| 2 | 0 | 8 |
0.023 0.020 [0.0-0.587] |
5 (62.5%) | 3 (37.5%) |
0.08 17.29 [0.712–419.95] |
3 (37.5%) | 5 (62.5%) |
0.512 2.40 [0.175–32.88] |
| 3 and 4 | 4 (80%) | 1 (20%) | 0 | 5 | 1 (20%) | 4 (80%) | |||
|
BMI (I) All patients |
|||||||||
| < 24.9 (N and UW) | 5 (12.2%) | 36 (87.8%) |
0.366 2.778 [0.303–25.46] |
22 (53.7%) | 19 (46.3%) |
0.181 0.463 [0.150–1.431] |
14 (34.1%) | 27 (65.9%) |
0.406 1.659 [0.503–5.475] |
| > 25.0 (OW) | 1 (4.8%) | 20 (95.2%) | 15 (71.4%) | 6 (28.6%) | 5 (23.8%) | 16 (76.2%) | |||
| < 18.5 (UW) | 3 (30%) | 7 (70%) |
0.033 7.0 [1.174–41.74] |
4 (40%) | 6 (60%) |
0.176 0.384 [0.096–1.534] |
3 (30%) | 7 (70%) |
0.962 0.964 [0.221–4.216] |
| > 18.5 (N and OW) | 3 (5.8%) | 49 (94.2%) | 33 (63.5%) | 19 (36.5%) | 16 (30.8%) | 36 (69.2%) | |||
|
BMI (I) Without parenteral nutrition |
|||||||||
| < 24.9 (N and UW) | 1 (3.1%) | 31 (96.9%) |
0.648 0.516 [0.030–8.805] |
19 (59.4%) | 13 (40.6%) |
0.237 0.450 [0.120–1.691] |
12 (37.5%) | 20 (62.5%) |
0.160 2.80 [0.665–11.79] |
| > 25.0 (OW) | 1 (5.9%) | 16 (94.1%) | 13 (76.5%) | 4 (23.5%) | 3 (17.6%) | 14 (82.4%) | |||
| < 18.5 (UW) | 0 | 7 |
0.962 2.80 [0.665–11.79] |
4 (57.1%) | 3 (42.9%) |
0.626 0.667 [0.131–3.398] |
3 (42.9%) | 4 (57.1%) |
0.453 1.875 [0.364–9.665] |
| > 18.5 (N and OW) | 2 (4.8%) | 40 (95.2%) | 28 (66.7%) | 14 (33.3%) | 12 (28.6%) | 30 (71.4%) | |||
|
BMI (I) Parenterally nourished |
|||||||||
| < 24.9 (N and UW) | 4 (44.4%) | 5 (55.6%) |
0.218 7.364 [0.307–176.42] |
3 (33.3%) | 6 (66.7%) |
0.571 0.50 [0.045–5.514] |
2 (22.2%) | 7 (77.8%) |
0.328 0.286 [0.023–3.524] |
| > 25.0 (OW) | 0 | 4 | 2 (50%) | 2 (50%) | 2 (50%) | 2 (50%) | |||
| < 18.5 (UW) | 3 | 0 |
0.030 44.33 [1.440-1365.15] |
0 | 3 |
0.232 0.143 [0.006–3.471] |
0 | 3 |
0.333 0.206 [0.008–5.051] |
| > 18.5 (N and OW) | 1 (10%) | 9 (90%) | 5 (50%) | 5 (50%) | 4 (40%) | 6 (60%) | |||
|
BMI (VII) All patients |
|||||||||
| < 24.9 (N and UW) | 6 (12.5%) | 42 (87.5%) |
0.320 4.435 [0.235–83.70] |
28 (58.3%) | 20 (41.7%) |
0.690 0.778 [0.226–2.673] |
14 (29.2%) | 34 (70.8%) |
0.641 0.741 [0.211–2.608] |
| > 25.0 (OW) | 0 | 14 | 9 (64.3%) | 5 (35.7%) | 5 (35.7%) | 9 (64.3%) | |||
| < 18.5 (UW) | 5 (33.3%) | 10 (66.7%) |
0.006 23.0 [2.416–218.95] |
8 (53.3%) | 7 (46.7%) |
0.566 0.709 [0.220–2.291] |
2 (13.3%) | 13 (86.7%) |
0.111 0.272 [0.055–1.349] |
| > 18.5 (N and OW) | 1 (2.1%) | 46 (97.9%) | 29 (61.7%) | 18 (38.3%) | 17 (36.2%) | 30 (63.8%) | |||
|
BMI (VII) Without parenteral nutrition |
|||||||||
| < 24.9 (N and UW) | 2 (5.1%) | 37 (94.9%) |
0.832 1.40 [0.062–31.47] |
26 (66.7%) | 13 (33.3%) |
0.693 1.333 [0.319–5.570] |
11 (28.2%) | 28 (71.8%) |
0.473 0.589 [0.139–2.499] |
| > 25.0 (OW) | 0 | 10 | 6 (60%) | 4 (40%) | 4 (40%) | 6 (60%) | |||
| < 18.5 (UW) | 2 (16.7%) | 10 (83.3%) |
0.07 17.86 [0.794–401.41] |
8 (66.7%) | 4 (33.3%) |
0.909 1.083 [0.273–4.293] |
2 (16.7%) | 10 (83.3%) |
0.240 0.370 [0.070–1.945] |
| > 18.5 (N and OW) | 0 | 37 | 24 (64.9%) | 13 (35.1%) | 13 (35.1%) | 24 (64.9%) | |||
|
BMI VII Parenterally nourished |
|||||||||
| < 24.9 (N and UW) | 4 (44.4%) | 5 (55.6%) |
0.218 7.364 [0.307–176.42] |
2 (22.2%) | 7 (77.8%) |
0.094 0.095 [0.006–1.498] |
3 (33.3%) | 6 (66.7%) |
0.765 1.50 [0.106–21.31] |
| > 25.0 (OW) | 0 | 4 | 3 (75%) | 1 (25%) | 1 (35%) | 3 (75%) | |||
| < 18.5 (UW) | 3 | 0 |
0.030 44.33 [1.440-1365.15] |
0 | 3 |
0.232 0.143 [0.005–3.471] |
0 | 3 |
0.333 0.206 [0.008–5.051] |
| > 18.5 (N and OW) | 1 (10%) | 9 (90%) | 5 (50%) | 5 (50%) | 4 (40%) | 6 (60%) | |||
|
Weight loss (I vs VII) All patients |
|||||||||
| < 5% | 4 (13.3%) | 26 (86.7%) |
0.356 2.308 [0.390–13.64] |
18 (60%) | 12 (40%) |
0.960 1.026 [0.372–2.833] |
8 (26.7%) | 22 (73.3%) |
0.511 0.694 [0.234–2.064] |
| > 5% | 2 (6.2%) | 30 (93.8%) | 19 (59.4%) | 13 (40.6%) | 11 (34.4%) | 21 (65.6%) | |||
| < 10% | 5 (12.5%) | 35 (87.5%) |
0.331 3.00 [0.328–27.46] |
22 (55%) | 18 (45%) |
0.314 0.570 [0.191-1.70] |
13 (32.5%) | 27 (67.5%) |
0.670 1.284 [0.407–4.047] |
| > 10% | 1 (4.5%) | 21 (95.5%) | 15 (68.2%) | 7 (31.8%) | 6 (27.3%) | 16 (72.7%) | |||
|
Weight loss (I vs VII) Without parenteral nutrition |
|||||||||
| < 5% | 2 (9.1%) | 20 (90.9%) |
0.227 6.707 [0.305–147.38] |
14 (63.6%) | 8 (36.5%) |
0.825 0.875 [0.269–2.851] |
6 (27.3%) | 16 (72.7%) |
0.648 0.750 [0.219–2.574] |
| > 5% | 0 | 27 | 18 (66.7%) | 9 (33.3%) | 9 (33.3%) | 18 (66.7%) | |||
| < 10% | 2 (6.5%) | 29 (93.5%) |
0.469 3.136 [0.143–69.02] |
18 (58.1%) | 13 (41.9%) |
0.169 0.396 [0.106–1.482] |
11 (35.5%) | 20 (64.5%) |
0.336 1.925 [0.508–7.298] |
| > 10% | 0 | 18 | 14 (77.8%) | 4 (22.2%) | 4 (22.2%) | 14 (77.8%) | |||
|
Weight loss (I vs VII) Parenterally nourished |
|||||||||
| < 5% | 2 (25%) | 6 (75%) |
0.571 0.50 [0.045–5.514] |
4 (50%) | 4 (50%) |
0.295 4.00 [0.299–53.47] |
2 (25%) | 6 (75%) |
0.571 0.50 [0.045–5.514] |
| > 5% | 2 (40%) | 3 (60%) | 1 (20%) | 4 (80%) | 2 (40%) | 3 (60%) | |||
| < 10% | 3 (33.3%) | 6 (66.7%) |
0.765 1.50 [0.106–21.31] |
4 (44.4%) | 5 (55.6%) |
0.512 2.40 [0.175–32.88] |
2 (22.2%) | 7 (77.8%) |
0.328 0.286 [0.023–3.524] |
| > 10% | 1 (25%) | 3 (75%) | 1 (25%) | 3 (75%) | 2 (50%) | 2 (50%) |
I Measurement conducted before the commencement of therapy, VII measurement conducted after the termination of therapy, UW underweight, OW overweight, N normal